Back to search

Article

Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR Mutation-Positive Lung Cancer with EFGR-TKI treatment: A Prospective, Single Arm, Phase II Study

2022-07-25

Abstract excerpt

<h4>Introduction: </h4> Early stereotactic body radiation therapy (SBRT) to the primary tumor combined with EFGR-TKI treatment may increase progression-free survive (PFS) by delaying resistance in patients with advanced EGFR-mutant NSCLC. Methods In this prospective, single arm phase II study, patients with advanced NSCLC were treated with EGFR TKI (Icotinib125mg tid or gefitinib 250mg qd) for one month followed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c91d0603-3dbd-52b1-b318-ef8bf8e8cabb
DOI
10.21203/rs.3.rs-1865693/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Failure Patterns of Early SBRT to the Primary Tumor in Advanced EGFR Mutation-Positive Lung Cancer with EFGR-TKI treatment: A Prospective, Single Arm, Phase II StudyDOI 10.21203/rs.3.rs-1865693/v1
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.Semantic proximity
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.Semantic proximity
EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung CancerSemantic proximity
Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.Semantic proximity
Concurrent afatinib and stereotactic body radiotherapy improved survival of patient with oligometastatic EGFR-mutated non-small cell lung cancer： A case study and literature reviewSemantic proximity
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.Semantic proximity
Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: A phase Ⅱ clinical trialSemantic proximity
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.Semantic proximity
Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI.Semantic proximity
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trialSemantic proximity
Primary lesion radiotherapy during first-line icotinib treatment in EGFR-mutated NSCLC patients with multiple metastases and no brain metastases: a single-center retrospective study.Semantic proximity
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].Semantic proximity
Select a neighboring publication to make it the new centre.